Sugi Predict

Sugi Predict / Compounds / SCHEMBL17683243

SCHEMBL17683243

SCHEMBL17683243

COc1ccc2c(-c3ccnc(Cl)n3)cn(C)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK2 Q9HBH9 7/20 0.53
▸ MKNK1 Q9BUB5 4/20 0.53
▸ ALDH1A1 P00352 1/20 0.45
▸ SCN9A Q15858 2/20 0.43
▸ DYRK1A Q13627 5/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ HTR5A P47898 1/20 0.43
▸ MAOA P21397 1/20 0.42
▸ GSK3B P49841 4/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ CDK7 P50613 1/20 0.41
▸ BTK Q06187 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.39
▸ DYRK3 O43781 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30337219 0.90 MKNK1 (0.53) MKNK2MKNK1HTR2CHTR2BHTR5A
SCHEMBL28987649 0.90 MKNK1 (0.53) MKNK2MKNK1HTR2CHTR2BHTR5A
SCHEMBL30337162 0.84 DYRK1A (0.46) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL28384419 0.84 DYRK1A (0.46) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL28243725 0.83 MKNK2 (0.45) MKNK2MKNK1DYRK1AMAOAGSK3B
SCHEMBL30337212 0.83 DYRK1A (0.45) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL19254846 0.83 DYRK1A (0.45) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL17490471 0.83 DYRK1A (0.45) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL30459718 0.82 DYRK1A (0.44) MKNK2MKNK1SCN9ADYRK1AGSK3B
SCHEMBL17683321 0.82 DYRK1A (0.44) MKNK2MKNK1SCN9ADYRK1AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974845-B Preparation method of Ornitinib intermediate 奥锐特药业股份有限公司 2024-09-20 — — CN disclosed
CN-117402143-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2024-01-16 — — CN disclosed
CN-117069700-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-11-17 — — CN disclosed
CN-117050062-A EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-11-14 — — CN disclosed
CN-111187221-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-09-26 — — CN disclosed
CN-111171000-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-09-01 — — CN disclosed
CN-111170999-B EGFR inhibitor and preparation and application thereof 上海翰森生物医药科技有限公司 2023-06-30 — — CN disclosed
CN-115974845-A Preparation method of oxitinib intermediate 奥锐特药业股份有限公司 2023-04-18 — — CN disclosed
EP-3205650-B1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2021-08-04 — — EP disclosed
EP-3205650-B1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2021-08-04 — — EP disclosed
US-10259820-B2 EGFR inhibitor, preparation method and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-16 — — US disclosed
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-04 — — US disclosed
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2019-04-04 — — US disclosed
CN-108530428-A Substituted pyrimidine derivatives and preparation method thereof and medicinal usage 四川海思科制药有限公司 2018-09-14 — — CN disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 — — US disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 — — US disclosed
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2017-11-02 — — US disclosed
EP-3205650-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2017-08-16 — — EP disclosed
EP-3205650-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2017-08-16 — — EP disclosed
WO-2016054987-A1 EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313714-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 MKNK2 2422/4885MKNK1 2279/4885ALDH1A1 2036/4885
US-20190100528-A1 EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF EGFR, ERBB2, ERBB4 MKNK2 2701/4885MKNK1 2644/4885ALDH1A1 2919/4885
US-10259820-B2 EGFR inhibitor, preparation method and use thereof EGFR, ERBB2, ERBB4 MKNK2 2422/4885MKNK1 2279/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.